CDA and cancer: The release of UTP and UDP by cancer cells has been hypothesized to be a determinant factor in CDA-dependent resistance to anti-PD-1 therapy, as CDA is engaged in a pathway leading to the synthesis and release of uracil nucleotides in cancer cells [11].